CGRP Forum
Send to a colleague
Register  Login
Home   |   About   |   About CGRP   |   News   |   Hot Topics   |   Trials    |   Resources   |   Contact

Latest News

Aimovig (erenumab) available for chronic migraine prophylaxis on NHS in Scotland

The Scottish Medicines Consortium (SMC) has ruled that adult patients with chronic migraine who have failed on at least three prior prophylactic treatments can be prescribed erenumab on the National Health Service (NHS).

Read more »

CGRP may help explain why migraine is more common in women

Women may be more sensitive to raised levels of CGRP than men, suggest new pre-clinical findings reported by US researchers. The results, from a study of pain responses in female rodents, may help explain why migraine is three times more common in women than men.

Read more »

Phase 2/3 study of BHV-3500 gets underway in acute treatment of migraine

The first patient has been enrolled in a Phase 2/3 double-blind, randomised, placebo-controlled, dose-ranging trial of the intranasal small molecule CGRP antagonist, BHV-3500, in the acute treatment of migraine.

Read more »

Ajovy (fremanezumab) approved for migraine prevention in Europe

The European Commission has granted Marketing Authorisation for Ajovy (fremanezumab) 225 mg for prophylaxis of migraine in adults who have at least four migraine days per month – the same indication approved for Aimovig (erenumab) and Emgality (galcanezumab).

Read more »

For all the other recent migraine news featured on the CGRP Forum click here »

Becoming a member is easy

Members have free open access simply by registering online.
Facebook Like us on Facebook
For the latest updates, CGRP news and analysis.
Twitter Follow us on Twitter
Hot topics, news and conference reports.
Educational Partners and Supporters (others pending) Logos
© Copyright CGRP Forum 2019. Please click here to unsubscribe from future mailings.